Back to Journals » Drug Design, Development and Therapy » Volume 13 » A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: the DOLATAV study
Please verify you are not a robot.